MedTrace Logo

Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation

NCT00628394 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2020-09-25

Study results available
· View outcomes & findings →

Summary

This research is being done because people with schizophrenia often have problems with thinking including learning, remembering, paying attention, and problem solving. During this study, we will test if cognitive remediation (computer games made to improve thinking), used along with a drug called atomoxetine, may help the problems in thinking as well as some of the symptoms of schizophrenia.

Conditions

  • Cognition in Schizophrenia

Interventions

DRUG

Atomoxetine

40mg 2po qam

DRUG

Placebo

40mg 2po qam

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Stanley Medical Research Institute

    collaborator OTHER

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Carol A Tamminga, MD · UT Southwestern Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00628394 on ClinicalTrials.gov